시장보고서
상품코드
1441316

세계의 신장암 치료제 시장 규모, 점유율, 성장 분석, 유형별, 최종 사용자별, 유통 채널별, 산업 예측(2023-2030년)

Global Kidney Cancer Drugs Market Size, Share, Growth Analysis, By Type(Renal Cell Carcinoma, Papillary Renal Cell Carcinoma), By End user, By Distribution Channel - Industry Forecast 2023-2030

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 신장암 치료제 시장 규모는 2022년 44억 달러로 평가되었고, 예측 기간(2024-2031년) 동안 5.50%의 연평균 복합 성장률(CAGR)로 2023년 46억 4,000만 달러에서 2031년에는 71억 2,000만 달러로 성장할 것으로 예상됩니다.

최근 몇 년동안 세계 신장암 치료제 시장은 의학 연구의 집중과 발전으로 인해 큰 변화를 겪고 있습니다. 표적 치료와 면역 치료의 혁신은 신장암 치료제의 전망을 재구성하고 환자들에게 보다 효과적이고 덜 침습적인 치료 옵션을 제공합니다. 신장암 치료제에 대한 수요 증가는 조기 발견에 대한 인식과 노력 증가로 인한 것입니다. 의료 기관과 제약사의 전략적 제휴는 새로운 약물과 치료법 개발을 촉진하고 있습니다. 시장별로는 병원과 오프라인 약국이 여전히 우위를 점하고 있는 가운데, 재택의료와 온라인 약국 부문이 크게 성장하고 있습니다. 현재 북미가 가장 큰 시장 점유율을 차지하고 있으며, 아시아태평양이 빠르게 성장하고 있습니다. 주목할 만한 트렌드는 신장암 환자의 삶의 질 향상에 초점을 맞춘 환자 중심 치료의 중요성이 커지고 있다는 점입니다. 시장 선도 기업들은 환자 치료 결과를 개선하고 신장암 치료제의 미래를 만들어 갑니다는 종합적인 목표를 가지고 혁신적인 치료법을 도입하기 위해 연구개발에 많은 투자를 함으로써 이러한 변화에 대응하고 있습니다.

목차

주요 요약

  • 시장 개요
  • 번영과 쇠퇴

조사 방법

  • 정보 조달
  • 2차/1차 정보원
  • 시장 규모 추정
  • 시장 전제조건과 제한

상위 시장 분석

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인
    • 기회
    • 성장 억제요인
    • 과제

주요 시장 인사이트

  • 기술 분석
  • 가격 분석
  • 공급망 분석
  • 밸류체인 분석
  • 시장 생태계
  • IP 분석
  • 무역 분석
  • 스타트업 분석
  • 원재료 분석
  • 혁신 매트릭스
  • 파이프라인 제품 분석
  • 거시경제 지표
  • 주요 투자 분석
  • 주요 성공 요인
  • 경쟁 정도

시장 역학과 전망

  • 시장 역학
    • 성장 촉진요인
    • 기회
    • 성장 억제요인
    • 과제
  • 규제 상황
  • Porter의 Five Forces 분석
  • 향후 혼란에 관한 특별 인사이트

세계의 신장암 치료제 시장 : 유형별

  • 시장 개요
  • 신장세포암(RCC)
  • 유두상 신세포암
  • 색소성 신세포암
  • 미분류 신장세포암
  • 전이성 세포암
  • 윌룸스 종양(신모세포종)
  • 신장 육종
  • 혈관성 지방종
  • 종양 세포종
  • 기타

세계의 신장암 치료제 시장 : 최종사용자별

  • 시장 개요
  • 병원
  • 재택치료
  • 전문 클리닉
  • 기타

세계의 신장암 치료제 시장 : 유통 채널별

  • 시장 개요
  • 병원 약국
  • 온라인 약국
  • 소매 약국

세계의 신장암 치료제 시장 규모 : 지역별

  • 시장 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 구도

  • 주요 5개사 비교
  • 주요 기업의 시장 포지셔닝(2021년)
  • 주요 시장 기업이 채택한 전략
  • 주요 성공 전략
  • 시장에서의 최근 활동
  • 주요 기업의 시장 점유율(2021년)

주요 기업 개요

  • Pfizer Inc(미국)
  • Aurobindo Pharma(인도)
  • Bristol-Myers Squibb Company(미국)
  • Sanofi(프랑스)
  • Abbott(미국)
  • Mylan N.V.(미국)
  • Sun Pharmaceutical Industries Ltd(인도)
  • F. Hoffmann-La Roche Ltd(스위스)
  • Novartis AG(스위스)
  • Takeda Pharmaceutical Company Limited(일본)
  • Cipla Inc(인도)
  • AstraZeneca(영국)
  • Fresenius SE & Co. KGaA(독일)
  • Dr. Reddy's Laboratories Ltd(인도)
  • Lupin(인도)
  • Teva Pharmaceutical Industries Ltd(이스라엘)
  • Endo International plc(아일랜드)
LSH 24.04.11

Global Kidney Cancer Drugs Market size was valued at USD 4.40 Billion in 2022 and is poised to grow from USD 4.64 Billion in 2023 to USD 7.12 Billion by 2031, at a CAGR of 5.50% during the forecast period (2024-2031).

Recent years have witnessed significant transformations in the global kidney cancer drugs market due to heightened focus and advancements in medical research. Innovations in targeted therapies and immunotherapies are reshaping the treatment landscape for kidney cancer, offering patients more effective and minimally invasive options. The increasing demand for kidney cancer treatments is driven by growing awareness and efforts in early detection. Strategic collaborations between healthcare institutions and pharmaceutical firms are fostering the development of novel drugs and treatment approaches. In terms of market segments, there has been substantial growth in the homecare and online pharmacy sectors, although hospitals and offline pharmacies continue to dominate. North America currently holds the largest market share, with the Asia-Pacific (APAC) region showing rapid growth rates. A notable trend is the growing importance of patient-centric care, with a strong focus on improving the quality of life for individuals with kidney cancer. Market players are responding to these shifts by investing heavily in research and development (R&D) to introduce innovative therapies, with the overarching goal of enhancing patient outcomes and shaping the future of kidney cancer treatment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Kidney Cancer Drugs and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Kidney Cancer Drugs Market Segmental Analysis

The global kidney cancer drugs market is segmented on the basis of type, end user, distribution channel and region. Based on type the market is segmented as renal cell carcinoma (RCC), papillary renal cell carcinoma, chromophobe renal cell carcinoma, unclassified renal cell carcinoma, transitional cell carcinoma, Wilms tumor (Nephroblastoma), renal sarcoma, angiomyolipoma, oncocytoma, others. On the basis of End user, the market is segmented as hospitals, homecare, specialty clinics, others. Based on the distribution channel, it is segregated into hospital pharmacy, online pharmacy, and retail pharmacy. Regionally speaking, the market can be segmented into several categories, which are North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Kidney Cancer Drugs Market

Immunotherapy stands out as a significant catalyst in the expansion of the kidney cancer drugs market. This innovative approach harnesses the body's immune system to identify and combat cancer cells. With its ability to enhance the body's natural defences, immunotherapy has demonstrated promising results in kidney cancer treatment, particularly for cases where traditional therapies have been less effective. Ongoing research aimed at unveiling new combinations of treatments and immunotherapeutic agents is providing patients with access to less invasive and more efficacious alternatives, significantly improving their prospects in managing kidney cancer.

Restraints in the Global Kidney Cancer Drugs Market

One of the significant challenges in the kidney cancer drugs market is the presence of stringent regulatory barriers. While these regulations are crucial for ensuring patient safety and the effectiveness of drugs, they often result in prolonged approval timelines for new treatments. The extensive clinical trials and complex documentation required in the regulatory process contribute to delays in the availability of innovative therapies in the market. Furthermore, the varying regulatory landscapes across different regions add another layer of complexity for pharmaceutical companies seeking global approvals. These challenges collectively hinder the timely introduction of potentially life-saving drugs into the market, limiting treatment options for kidney cancer patients.

Market Trends of the Global Kidney Cancer Drugs Market

An important trend shaping the kidney cancer drugs market is the move towards personalized treatment strategies. This shift is driven by advancements in molecular diagnostics and genetic profiling, which enable the identification of specific biomarkers. These biomarkers facilitate the development of customized therapies tailored to individual patient characteristics. This trend represents a significant advancement in kidney cancer care, as it improves treatment efficacy while minimizing potential side effects.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Kidney Cancer Drugs Market by Type

  • Market Overview
  • Renal Cell Carcinoma (RCC)
  • Papillary Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Unclassified Renal Cell Carcinoma
  • Transitional Cell Carcinoma
  • Wilms Tumor (Nephroblastoma)
  • Renal Sarcoma
  • Angiomyolipoma
  • Oncocytoma
  • Others

Global Kidney Cancer Drugs Market by End user

  • Market Overview
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Global Kidney Cancer Drugs Market by Distribution Channel

  • Market Overview
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Global Kidney Cancer Drugs Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Pfizer Inc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurobindo Pharma (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Inc (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius SE & Co. KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lupin (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Endo International plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제